My Cart

0 Item(s): $0.00

You have no items in your shopping cart.

linagliptin brand name

linagliptin brand name


Linagliptin is used together with proper diet and exercise to treat high blood sugar levels caused by type 2 diabetes. Linagliptin helps to control blood sugar levels by increasing substances in the body that make the pancreas release more insulin. It also signals the liver to stop producing sugar (glucose) when there is too much sugar in the blood. This medicine does not help patients who have insulin-dependent or type 1 diabetes.

Dosage and administration

Recommended Dosage

The recommended dose of GLYXAMBI is 10 mg empagliflozin/5 mg linagliptin once daily in the morning, taken with or without food. In patients tolerating GLYXAMBI, the dose may be increased to 25 mg empagliflozin/5 mg linagliptin once daily.

In patients with volume depletion, correcting this condition prior to initiation of GLYXAMBI is recommended [see WARNINGS AND PRECAUTIONS, Use In Specific Populations and PATIENT INFORMATION].

No studies have been performed specifically examining the safety and efficacy of GLYXAMBI in patients previously treated with other oral antihyperglycemic agents and switched to GLYXAMBI. Any change in therapy of type 2 diabetes should be undertaken with care and appropriate monitoring as changes in glycemic control can occur.

Mechanism of Action:

Linagliptin inhibits dipeptidyl peptidase-4, an enzyme that degrades the incretin hormones

glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). GLP-1

and GIP are involved in the maintenance of glucose homeostasis. These hormones stimulate

the release of insulin in a glucose-dependent manner, by increasing insulin biosynthesis and

secretion from pancreatic beta cells in the presence of normal and elevated blood glucose

levels. GLP-1 also decreases the glucagon secretion from pancreatic alpha cells, which results

in a reduction in hepatic glucose production.

Linagliptin inhibits the degradation of these hormones by DPP-4, thereby increasing insulin release in a glucose-dependent manner and decreasing the levels of circulating glucagon. Linagliptin is beneficial in patients with type 2 DM as their GLP-1 concentrations are decreased in response to a meal.

What are the side effects of linagliptin?

The most common side effects of Tradjenta are:

  • Stuffy or runny nose
  • Sore throat
  • Allergic reactions
  • Muscle pain
  • Diarrhea
  • Increased uric acid levels
  • Cough
  • Pancreatitis
  • Severe joint pain
  • Severe allergic reactions (anaphalaxis)


Linagliptin 5-mg and 100-mg doses were well tolerated when administered as single doses.

There were no clinically significant laboratory abnormalities reported and no clinically relevant

abnormalities observed in the ECGs of any of the subjects. Vital signs were normal throughout

the study. Tolerability was rated as ‘good’ for all subjects and treatments by the investigator.

The drug-related adverse event most commonly reported was headache, which was observed

in all treatment groups. Breast cancer was reported as a serious adverse event and was

considered unrelated to study medication by the investigator. Linagliptin does not cause

clinically relevant changes of the corrected QT interval with a therapeutic dose and a 20-fold

therapeutic dose. The 20-fold therapeutic dose of linagliptin was safe and well tolerated.

Therapeutic and significantly supratherapeutic exposure to linagliptin is not associated with QT

interval prolongation.

Know More About This Medicine and Buy Now :